Hepatitis

Two Hepatitis C Virus Infection Treatments to Be Discontinued

Two Hepatitis C Virus Infection Treatments to Be Discontinued

By

The discontinuation is voluntary and is not related to product quality, safety or efficacy.

HBV Status Linked to Disease Activity and Progression in Rheumatoid Arthritis

HBV Status Linked to Disease Activity and Progression in Rheumatoid Arthritis

Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.

Hepatitis C-Exposed Infants Not Adequately Screened

Hepatitis C-Exposed Infants Not Adequately Screened

Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women.

Real-Life Renal Outcomes With Sofosbuvir in Chronic Hepatitis C

Real-Life Renal Outcomes With Sofosbuvir in Chronic Hepatitis C

Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up.

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

By

The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Screening insufficient for newborns exposed to hepatitis C virus

In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

By

Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.

CDC: Recommendations on the Use of Heplisav-B Published

CDC: Recommendations on the Use of Heplisav-B Published

By

The CDC has published ACIP recommendations regarding the use of Heplisav-B.

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

By

Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.

How San Francisco Is Tackling the HIV/HCV and Opioid Epidemics

How San Francisco Is Tackling the HIV/HCV and Opioid Epidemics

By

Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal use of tenofovir disoproxil fumarate does not lower hepatitis B virus transmission rates.

BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus

BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus

For patients with chronic HBV, BMI is significantly associated with increased risk of hepatocellular carcinoma.

Hepatitis C Screening Increasing Among Baby Boomers

Hepatitis C Screening Increasing Among Baby Boomers

Future research should develop interventions to increase HCV screening with special focus on groups demonstrating significantly lower screening rates, such as Hispanics and women.

Accelerated Cortical Aging With Alcohol Dependence in HCV-Infected Individuals

Accelerated Cortical Aging With Alcohol Dependence in HCV-Infected Individuals

Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus infection and drug dependence.

Hepatitis C Eradication With DAAs Improves Carotid Atherosclerosis

Hepatitis C Eradication With DAAs Improves Carotid Atherosclerosis

By

HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

No difference between tenofovir and placebo in reducing perinatal transmission of hepatitis B

Hepatitis B e-antigen positive mothers receiving tenofovir daily from 28-weeks gestation to 2 months postpartum did not show significant reductions in HBV transmission rates compared to placebo treated participants.

HCV-infected kidney donors could save lives

No HCV infection was detected in patients receiving HCV-infected kidneys 12 weeks following treatment.

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

By

The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.

Case of Psoriasis Remission After Hepatitis C Treatment

Case of Psoriasis Remission After Hepatitis C Treatment

A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.

ACIP Issues Updated Recommendations for Preventing HBV Infection

ACIP Issues Updated Recommendations for Preventing HBV Infection

By

The Advisory Committee on Immunization Practices has issued updated recommendations for HBV prevention.

New Two-Dose Hepatitis B Vaccine for Adults Now Available

New Two-Dose Hepatitis B Vaccine for Adults Now Available

By

Dynavax Technologies announced the availability of a two-dose hepatitis B vaccine for adults.

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.

Hepatitis B Vaccination Prevalence Low in Patients With HIV

Hepatitis B Vaccination Prevalence Low in Patients With HIV

More than one-third of adult US HIV patients miss opportunities to initiate hepatitis B vaccination.

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

By

State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.

Treatment Regimens and Recommendations for HIV/HCV Coinfection

Treatment Regimens and Recommendations for HIV/HCV Coinfection

By

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

By

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

By

Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

By

Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.

Sign Up for Free e-newsletters